Oryzon Genomics S.A. (0RDB.L)
0RDB.L Stock Price Chart
Explore Oryzon Genomics S.A. interactive price chart. Choose custom timeframes to analyze 0RDB.L price movements and trends.
0RDB.L Company Profile
Discover essential business fundamentals and corporate details for Oryzon Genomics S.A. (0RDB.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
15 Dec 2016
Employees
47.00
Website
https://www.oryzon.comCEO
Carlos Manuel Buesa Arjol
Description
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
0RDB.L Financial Timeline
Browse a chronological timeline of Oryzon Genomics S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 22 Oct 2025
Earnings released on 30 Jul 2025
Earnings released on 12 May 2025
EPS came in at -€0.03 surpassing the estimated -€0.03 by +3.04%.
Earnings released on 24 Feb 2025
EPS came in at -€0.02 surpassing the estimated -€0.02 by +24.52%, while revenue for the quarter reached €7.36M , beating expectations by +674.90%.
Earnings released on 24 Oct 2024
EPS came in at -€0.02 falling short of the estimated -€0.02 by -8.59%, while revenue for the quarter reached €750.00K .
Earnings released on 31 Jul 2024
EPS came in at €0.00 surpassing the estimated -€0.01 by +119.66%, while revenue for the quarter reached €4.10M .
Earnings released on 6 May 2024
EPS came in at -€0.02 surpassing the estimated -€0.03 by +31.95%.
Earnings released on 27 Feb 2024
EPS came in at -€0.03 surpassing the estimated -€0.05 by +44.99%, while revenue for the quarter reached €14.24M .
Earnings released on 30 Sept 2023
EPS came in at -€0.02 surpassing the estimated -€0.04 by +56.17%.
Earnings released on 30 Jun 2023
EPS came in at €0.02 surpassing the estimated -€0.03 by +166.64%, while revenue for the quarter reached €7.49M .
Earnings released on 31 Mar 2023
EPS came in at -€0.03 falling short of the estimated -€0.03 by -3.47%.
Earnings released on 31 Dec 2022
EPS came in at -€0.04 falling short of the estimated -€0.04 by -4.76%, while revenue for the quarter reached €15.62M .
Earnings released on 30 Sept 2022
EPS came in at -€0.01 surpassing the estimated -€0.05 by +77.50%.
Earnings released on 30 Jun 2022
EPS came in at €0.01 surpassing the estimated -€0.04 by +120.93%, while revenue for the quarter reached €7.20M .
Earnings released on 31 Mar 2022
EPS came in at -€0.03 .
Dividend declared on 15 Mar 2022
A dividend of €0.29 per share was announced, adjusted to €0.29.
Earnings released on 31 Dec 2021
EPS came in at -€0.04 surpassing the estimated -€0.05 by +19.65%, while revenue for the quarter reached €10.66M .
Earnings released on 30 Sept 2021
EPS came in at -€0.03 .
Earnings released on 30 Jun 2021
EPS came in at €0.01 surpassing the estimated -€0.03 by +158.46%, while revenue for the quarter reached €4.90M .
Earnings released on 31 Mar 2021
EPS came in at -€0.03 .
Earnings released on 31 Dec 2020
EPS came in at -€0.02 , while revenue for the quarter reached €2.26M .
Earnings released on 30 Sept 2020
EPS came in at -€0.01 , while revenue for the quarter reached €1.30M .
0RDB.L Stock Performance
Access detailed 0RDB.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.